Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort
NCT ID: NCT01303523
Last Updated: 2015-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1627 participants
OBSERVATIONAL
2010-12-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiological Characteristics and Prevention Methods of Blisters in Ultra-trail Runners
NCT05071651
Fitness- and Health-related Effects of a Sports Injury Prevention Program in Competitive Alpine Skiers
NCT04021576
A 13-years Nationwide Study of Alpine Accidents in Austria
NCT03755050
Sport Without Injury ProgrammE Floorball
NCT03309904
Epidemiology of Injuries in Elite Badminton Players: a Prospective Study
NCT04181242
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A 3 month follow-up by phone will be realized by the Investigation Clinical Center in Grenoble. Data about risk factors of thromboembolic diseases, anticoagulant therapy, medical history, new event since inclusion (hospitalization, surgery, lower limb trauma or thromboembolic events) will be collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* lower limb trauma seen within 48 hours
* patient resident in France
Exclusion Criteria
* prisoners
* pregnant, nursing or parturient woman
* refused participation in follow-up
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Floralis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominique LAMY, MD
Role: PRINCIPAL_INVESTIGATOR
Médecins de Montagne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
medical center "Le chevreuil"
Autrans, , France
Medical center "le pas du lac"
Avoriaz, , France
Medical center "les Soldanelles"
Bellevaux, , France
Medical center "le serre d'aigle"
Chantemerle, , France
Medical center of Combloux
Combloux, , France
Medical home
Flaine, , France
Medical center of flumet
Flumet, , France
Medical Center Brousse
Font-Romeu-Odeillo-Via, , France
Medical center of Beauregard - "les cyclamens"
La Clusaz, , France
Medical group "le Yéti"
La Clusaz, , France
Medical center
Lanslevillard, , France
Medical group "SELARL Sports médecine montagne"
Le Grand-Bornand, , France
Medical group of Peric
Les Angles, , France
Medical center of "Aiguille rouge"
Les Arcs, , France
Medical center "Val Montjoie"
Les Contamines-Montjoie, , France
SCP medical "le Bennevy"
Les Gets, , France
Medical center
Les Orres, , France
Medical center
Lullin, , France
Medical center of Jaillet
Megève, , France
Medical center of Peisey-Vallandry
Peisey Vallandry, , France
Resort of Peyragudes
Peyragudes, , France
Medical center "le rocher de l'aigle"
Saint-François-Longchamp, , France
Medical center "Fleur des alpes"
Saint-Gervais-les-Bains, , France
Medical center
Samoëns, , France
Medical center "medival"
Val-d'Isère, , France
Medical center of Valberg
Valberg Guillaumes, , France
Medical center
Vallouise, , France
Medical center
Villard-de-Lans, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Motykie GD, Zebala LP, Caprini JA, Lee CE, Arcelus JI, Reyna JJ, Cohen EB. A guide to venous thromboembolism risk factor assessment. J Thromb Thrombolysis. 2000 Apr;9(3):253-62. doi: 10.1023/a:1018770712660. No abstract available.
Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S4-13. doi: 10.1093/ajhp/58.suppl_2.S4.
Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol. 2010 Jun;149(6):824-33. doi: 10.1111/j.1365-2141.2010.08206.x. Epub 2010 Apr 29.
Gensini GF, Prisco D, Falciani M, Comeglio M, Colella A. Identification of candidates for prevention of venous thromboembolism. Semin Thromb Hemost. 1997;23(1):55-67. doi: 10.1055/s-2007-996071.
Eschwege V, Robert A. Strikes in French public transport and resistance to activated protein C. Lancet. 1996 Jan 20;347(8995):206. doi: 10.1016/s0140-6736(96)90393-1. No abstract available.
Vaitkus PT, Leizorovicz A, Goldhaber SZ; PREVENT Investigator Group. Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vasc Med. 2002;7(4):269-73. doi: 10.1191/1358863x02vm449oa.
Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006 Feb 11;332(7537):325-9. doi: 10.1136/bmj.38733.466748.7C. Epub 2006 Jan 26.
Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. Haemostasis. 1993 Mar;23 Suppl 1:20-6. doi: 10.1159/000216905.
Jorgensen PS, Warming T, Hansen K, Paltved C, Vibeke Berg H, Jensen R, Kirchhoff-Jensen R, Kjaer L, Kerbouche N, Leth-Espensen P, Narvestad E, Rasmussen SW, Sloth C, Torholm C, Wille-Jorgensen P. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study. Thromb Res. 2002 Mar 15;105(6):477-80. doi: 10.1016/s0049-3848(02)00059-2.
Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med. 2002 Sep 5;347(10):726-30. doi: 10.1056/NEJMoa011327.
Riou B, Rothmann C, Lecoules N, Bouvat E, Bosson JL, Ravaud P, Samama CM, Hamadouche M. Incidence and risk factors for venous thromboembolism in patients with nonsurgical isolated lower limb injuries. Am J Emerg Med. 2007 Jun;25(5):502-8. doi: 10.1016/j.ajem.2006.09.012.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DCIC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.